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We investigated the evolution of cortical atrophy in patients with early relapsing-remitting (RR) multiple sclerosis (MS) and its
association with lesion volume (LV) accumulation and disability progression. 136 of 181 RRMS patients who participated in the
Avonex-Steroids-AzathioprinestudywereassessedbimonthlyforclinicalandMRIoutcomesover2years.MSpatientswithdisease
duration (DD) at baseline of ≤24 months were classi�ed in the early group (DD of 1.2 years, 𝑛𝑛 𝑛 𝑛𝑛), while patients with DD >
24 months were classi�ed in the late group (DD of �.1 years, 𝑛𝑛 𝑛 𝑛𝑛). Mixed eﬀect model analysis was used to investigate the
associations. Signi�cant changes in whole brain volume (WBV) (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃 ), cortical volume (CV) (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃 ), and in T2-LV
(𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃 ) were detected. No signi�cant MRI percent change diﬀerences were detected between early and late DD groups over
2 years, except for increased T2-LV accumulation between baseline and year 2 in the early DD group (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 ). No signi�cant
associationswerefoundbetweenchangesinT2-LVandCVoverthefollowup.ChangeinCVwasrelatedtothedisabilityprogression
overthe2years,aeradjustingforDD(𝑃𝑃 𝑛 𝑃𝑃𝑃𝑃).Signi�cantcorticalatrophy,independentofT2-LVaccumulation,occursinearly
RRMS over 2 years, and it is associated with the disability progression.
1. Introduction
Multiple sclerosis (MS) is an autoimmune disease of the
central nervous system (CNS) that aﬀects both white matter
(WM) and gray matter (GM).
In the last decade, there has been increased interest
in studying GM damage in MS, especially in the cortical
regions [1]. Advances in both MRI acquisition and analysis
techniques have enabled better detection of changes in GM
morphology [2]. e MRI assessments included measure-
ments of cortical atrophy, cortical thinning, and cortical
lesions [1–4].
Becauseimagingtechniquesarestillunabletoadequately
detect GM lesions, especially in the cortex [5–9], measure-
ment of cortical atrophy is gaining increasing attention in
the literature [1], in order to assess the real extent of cortical
pathology in vivo in patients with MS [2].
Recent studies have established that subcortical, but not
cortical, atrophy is present at the earliest clinical stages of
the disease [10–15]. However, most of these studies had
a cross-sectional design, and only a few longitudinal stud-
ies investigated possible associations between GM atrophy
and clinical outcomes in patients with MS [11, 15–18].2 Multiple Sclerosis International
In addition, only one serial MRI study investigated the evo-
lution of GM atrophy over a 9-month period [19]. erefore,
one of the main goals of this study was to investigate the
bimonthlyevolution of cortical atrophyin patients with early
relapsing-remitting (RR) MS over a period of 2 years.
In�ammatory activity in the WM is histopathologically
diﬀerent from changes in the GM [4, 20, 21]. Some of the
processes in the cortex even precede changes in WM and are
probably more responsible for development of irreversible
clinical disability [15–19, 22–24]. Very few longitudinal
studies explored the relationship between cortical atrophy
development and WM lesion burden accumulation and
disability progression in early RRMS [11, 18]. erefore,
another aim of this study was to investigate the eﬀect of
corticalatrophydevelopmentondisabilityprogression,using
bimonthly serial MRI assessments. We also assessed the
relationshipbetweenaccumulationofWMlesionburdenand
development of cortical atrophy.
2. Methods
2.1. Patients. MRI data were obtained from patients who
were initially enrolled into the 2-year, double-blind, placebo-
controlled Avonex-Steroids-Azathioprine (ASA) study [25].
Inthisstudy,181patientswererandomizedtotreatmentwith
intramuscular (IM) interferon beta (IFN𝗽𝗽) 1a (30𝜇𝜇g/week)
alone or in combination with azathioprine (50mg/day) or
azathioprine plus prednisone (10mg every other day). Full
details of the design, inclusion and exclusion criteria and
results of the 2-year study (by randomized treatment group)
[25], and preliminary results from the extension 5-year
period (by disability progression) were previously reported
[18, 26]. In the original study there were no signi�cant
diﬀerences regarding clinical or MRI outcomes during the
2 years, except the change from baseline in T2-LV that
favored the triple-agent combination therapy versus IFN𝗽𝗽-
1a monotherapy (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃)[ 25]. However, a recent 6-year
followup evaluation of the ASA study by original treatment
arm reported no signi�cant diﬀerence in the absolute T2-LV
and its changes over 6 years between the original treatment
groups [27], suggesting that original percent change of T2-
LV diﬀerences were probably in�ated by the lower baseline
T2-LVintheIMIFN𝗽𝗽-1aalonegroup.erefore,thepresent
study represents a post-hoc analysis of combined patients
who had complete clinical and MRI assessments and who
participated in a serial MRI substudy over 2 years.
Both MRI and standard clinical assessments were con-
ducted at baseline at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,
and 24 months (13 time-points) over a two year period. e
sustained disability progression was assessed at 27 months
andwasde�nedasa≥1.0-pointsustained(12-week)increase
in the EDSS score in patients who had a baseline EDSS score
of ≥1.0 or a ≥1.5-point sustained (12-week) increase in the
EDSS score in patients who had a baseline EDSS score of 0.0.
estudywasapprovedbytheMedicalEthicsCommittee
of the General University Hospital and the First Faculty of
Medicine,CharlesUniversity in Prague,CzechRepublic,and
by the University at Buﬀalo, NY, USA.
2.2. MRI Imaging and Analysis. All MRI assessments were
performedusingthesamePhilipsGyroscan1.5-Teslascanner
(Philips Medical Systems, Best, e Netherlands), located in
theDepartmentofRadiologyatCharlesUniversityinPrague.
Axial images of the brain were acquired using fast �uid-
attenuated inversion recovery (FLAIR) with 1.5-mm slice
thickness and axial T1-weighted 3-dimensional (3D) spoiled
gradient-recalled (SPGR) images with 1mm slice thickness.
All images were nongapped. MRI assessment protocols were
conducted as previously reported [18, 25, 26].
All serial bimonthly MRI scans (2, 4, 6, 8, 10, 12, 14, 16,
18,20,22,and24months)wereanalyzedbytheBuﬀaloNeu-
roimaging Analysis Center at the Department of Neurology,
University at Buﬀalo, NY, USA. Investigators performing the
image analyses were blinded to subject characteristics and
clinical or treatment status.
T2 lesion volumes (LVs) were calculated using a reliable
contouring-thresholding technique, as previously reported
[28]. Volumetric measures were determined on T1-weighted
3D SPGR images that were modi�ed by using an in-house
developed inpainting technique to avoid tissue misclassi�ca-
tion [28]. Structural image evaluation using normalization
of atrophy cross-sectional (SIENAX) [29] was used to obtain
normalized whole brain volume (WBV) and cortical volume
(CV). For longitudinal changes of the WBV, we applied the
SIENA method [29].
2.3. Statistical Analysis. Statistical analysis was performed
using SPSS 13.0 (SPSS, Chicago, IL, USA) and SAS 9.0 (SAS
Institute, Raleigh, NC, USA).
MSpatientswereclassi�edintotwogroupsbasedontheir
diseasedurationatbaseline.Patientswithdiseasedurationof
≤24 months were considered the early group, while patients
with disease duration lasting >24 months were considered
the late group. irty-seven patients were classi�ed into the
early group, while 99 patients were classi�ed into the late
group. e demographic, clinical, and MRI characteristics at
baseline and over the followup were explored for the total
MS cohort, as well as the early and late disease duration
groups. e statistical diﬀerences at baseline and at follow-
up between the early and late disease duration groups were
calculated using the chi-square test, Student’s 𝑡𝑡-test, and
Mann-Whitney rank-sum test, as appropriate.
e Wilcoxon signed-rank test was used to test for any
signi�cant changes within individual groups between the
baseline and year 1 and year 2 measurements. Bimonthly
within individual group changes in CV were calculated using
the Kruskal-Wallis test.
Due to the repeated measures and the nature of the serial
MRIdataacquisitiontimepoints(bimonthly),andinorderto
estimate the longitudinal eﬀect of cortical atrophy in relation
to lesion burden accumulation and disability progression,
we used regression (for baseline) and mixed eﬀect model
(for followup) analyses [30]. e analysis was performed
s e p a r a t e l yf o rt h et o t a lM Sc o h o r ta n de a r l ya n dl a t ed i s e a s e
duration groups.
In order to avoid too many spurious �ndings due to mul-
tiple comparisons, we do not report anything as statisticallyMultiple Sclerosis International 3
T 1: Descriptive statistics of demographic, clinical, and MRI variables at baseline.
Total (𝑛𝑛 𝑛 𝑛𝑛𝑛) Early group (𝑛𝑛 𝑛 𝑛𝑛) Late group (𝑛𝑛 𝑛 𝑛𝑛) 𝑃𝑃 value
∗
Sex, females (%) 108 (79.4%) 32 (86.5) 76 (76.8) 0.243
Age in years, mean (SD) min–max 30.9 (7.9) 19–56 27.3 (6.7) 19–50 32.2 (7.9) 19.6–56 0.001
Age at onset in years, mean (SD)
min–max 23.9 (7.1) 12–51 24.8 (6.5) 18–48 23.5 (7.3) 12–51 0.345
Annual relapse rate, mean (SD)
min–max 1.8 (0.8) 0–4 2 (0.83) 0–4 1.8 (0.7) 0–3 0.064
Disease duration in years, mean (SD)
median (min–max) 5.5 (5.2) 3.9 ( 0.6–32.5) 1.24 (0.37) 1.2 (0.6–2) 7.1 (5.3) 5.4 (2.1–32.5) <0.0001
EDSS, mean (SD) median (min–max) 1.9 (0.9) 2.0 (0–4.0) 1.5 (0.9) 1.5 (0–3.5) 2.1 (0.9) 2.0 (0–4.0) 0.002
Normalized WBV, mean (SD)
min–max 1494 (76.7) 1303.1–1667.1 1524.3 (64.8)
1393.3–1649.8
1482.6 (77.9)
1303.1–1667.1 0.014
Normalized CV, mean (SD) min–max 587.5 (44.2) 478.9–685.9 608 (34.7) 537.8–685.9 579.8 (45.1) 478.8–670.3 0.002
T2-LV, mean (SD) min–max 10 (11.1) 0.1–58.3 5.9 (6.4) 0.1–24.2 11.5 (12.1) 0.2–58.3 0.01
EDSS: expanded disability status scale, WBV: whole brain volume, CV: cortical volume, and LV: lesion volume.
Annual relapse rate refers to the mean number of relapses in the year before baseline.
e statistical diﬀerences between early and late disease duration groups (𝑃𝑃 value
∗) were calculated using the chi-square test, Student’s 𝑡𝑡-test, and Mann-
Whitney rank-sum test, as appropriate.
e volumes are reported in milliliters.
signi�cant unless the nominal 𝑃𝑃 value was ≤0.01 by using
two-tailed tests.
3. Results
3.1. Demographic, Clinical, and MRI Characteristics at Base-
line. Table 1 shows demographic, clinical, and MRI charac-
teristics of the total MS cohort (𝑛𝑛 𝑛 𝑛𝑛𝑛) ,a sw e l la so ft h e
early (𝑛𝑛𝑛𝑛 𝑛 )a n dl a t e( 𝑛𝑛𝑛𝑛 𝑛 ) disease duration groups. No
signi�cant diﬀerences were found in baseline demographic,
clinical and MRI characteristics between the MS cohort who
participated in serial bimonthly MRI ASA study (𝑛𝑛 𝑛 𝑛𝑛𝑛)
compared to the total MS cohort participating in the ASA
study (𝑛𝑛 𝑛 𝑛𝑛𝑛).
Mean disease duration at baseline was 5.5 years for all
the patients, with 1.2 years among the early and 7.1 years
among the late groups (𝑃𝑃 <𝑃𝑃𝑃𝑃𝑃𝑛). As expected, the
early disease duration group had a signi�cantly lower age at
baseline (27.3 years) compared to the late group (32.2 years).
No diﬀerences were observed between the two groups in
age at onset. e mean EDSS at baseline was 1.9 among all
patients in the study, with the late disease duration group
having a signi�cantly increased EDSS compared to the early
one (𝑃𝑃 𝑛 𝑃𝑃𝑃𝑃𝑃).
e late disease duration group had a signi�cantly de-
creased normalized CV (𝑃𝑃 𝑛 𝑃𝑃𝑃𝑃𝑃), normalized WBV (𝑃𝑃𝑛
𝑃𝑃𝑃𝑛), and increased T2-LV (𝑃𝑃 𝑛 𝑃𝑃𝑃𝑛) at baseline compared
t ot h ee a r l yg r o u p .
ere were no signi�cant diﬀerences in the original
treatmentarmfrequencydistribution(IFN𝗽𝗽-1aalone,IFN𝗽𝗽-
1a + AZA, and IFN𝗽𝗽-1a + AZA + Prednisone) between the
early (32%, 33% and 35%, resp.,) and late (32%, 34%, and
34%, resp.,) disease duration groups.
3.2. MRI Outcomes Over the Followup. Signi�cant diﬀer-
ences within individual total, early, and late disease duration
groups were detected for % changes in WBV (𝑃𝑃 <𝑃𝑃𝑃𝑃𝑛) and
CV (𝑃𝑃 <𝑃𝑃𝑃𝑃𝑛) between baseline and year 1 and baseline
and year 2 (Table 2). In the total MS cohort, there was no
signi�cant increase in T2-LV between baseline and year 1
only, while there was a signi�cant increase within individual
total, early, and late disease duration groups between year 1
a n dy e a r2a n db a s e l i n ea n dy e a r2( 𝑃𝑃 <𝑃𝑃𝑃𝑃𝑛).
e highest % changes in MRI measures were detected
in the early disease duration group between baseline and
year 2 for CV (−2.48%), WBV (−2.11%), and T2-LV (48.3%).
However, only the increase in T2-LV between baseline and
year 2 resulted in a signi�cant diﬀerence between the early
and late disease duration groups (𝑃𝑃 <𝑃𝑃𝑃𝑛).
Evolution of bimonthly % CV changes is shown in
Figure 1. Signi�cant diﬀerences within individual total, early,
and late disease duration groups were detected in CV over 2
years (𝑃𝑃 <𝑃𝑃𝑃𝑃𝑃𝑛).
3.3. Bimonthly Eﬀect of T2-LV Accumulation on Cortical
Volume Changes. Table 3 representstheregression(baseline)
and mixed eﬀect model (year 1 and year 2) analyses results
between T2-LV and CV for the total MS cohort, using all
serial MRI time points of the study. Aer adjusting for
patients’ age and disease duration, we found that higher
T2-LV at baseline was strongly related to decreased CV at
baseline (𝑃𝑃 <𝑃𝑃𝑃𝑃𝑃𝑛). Nevertheless, the % change in T2-
LV at year 1 was not signi�cantly related to the % change
in CV over 1 year. Similarly, the change in T2-LV was not
signi�cantly related to the change in CV between year 1 and
y e a r2o rb a s e l i n et oy e a r2 .4 Multiple Sclerosis International
T 2: Changes in MRI outcomes over 2 years between diﬀerent study groups.
Total
(𝑛𝑛 𝑛 𝑛𝑛𝑛)
mean (SD) median
Early group
(𝑛𝑛 𝑛 𝑛𝑛)
mean (SD) median
Late group
(𝑛𝑛 𝑛 𝑛𝑛)
mean (SD) median
𝑃𝑃 value
∗
% Change in WBV (0-1 years) −1.59 (3.9) −1.32
∗∗∗ −2.11 (3.5) −1.84
∗∗∗ −1.39 (4.1) −1.1
∗∗∗ 0.531
% Change in WBV (1-2 years) 0.12 (5.3) −0.34 0.05 (3.4) −0.35 0.15 (5.9) −0.23 0.428
% Change in WBV (0–2 years) −1.61 (3) −.37
∗∗∗ −2.23 (2.8) −2.2
∗∗∗ −1.37 (3.1) −0.98
∗∗∗ 0.751
% Change in CV (0-1 years) −2.15 (4.3) 1.78
∗∗∗ −2.31 (3.5) −1.88
∗∗∗ −2.1 (4.6) −1.77
∗∗∗ 0.559
% Change in CV (1-2 years) −0.01 (6.9) −0.09 −0.53 (4.7) −1.36 0.21 (6.6) −0.06 0.140
% Change in CV (0–2 years) −2.22 (4) −2.28
∗∗∗ −2.48 (4) −2.98
∗∗∗ −2.12 (4) −1.98
∗∗∗ 0.606
% Change in T2-LV (0-1 years) 9.3 (43.6) 5.6
∗ 11.8 (48.5) 9 8.8 (40.6) 4.7 0.442
% Change in T2-LV (1-2 years) 28.1 (47.6) 19.5
∗∗∗ 38.6 (47.7) 29.5
∗∗∗ 24 (47) 16.1
∗∗∗ 0.091
% Change in T2-LV (0–2 years) 33.9 (52.8) 24.4
∗∗∗ 48.3 (57.5) 41.8
∗∗∗ 28.3 (49.9) 19.8
∗∗∗ 0.015
WBV: whole brain volume, CV: cortical volume, and LV: lesion volume.
Statistical diﬀerences between the early and late disease duration groups (𝑃𝑃 value
∗) were calculated using Student’s 𝑡𝑡-test.
e Wilcoxon signed-rank test was used to test within group % changes of the paired measures involving the baseline and the followup indices (
∗∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑛 ,
∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑛 , and
∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 ).
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F 1: Bimonthly cortical volume percent changes in total multiple sclerosis cohort (a), early (b), and late (c) disease duration groups.
Similar analyses were also performed in the two disease
duration groups (early and late) both with and without age
asacovariate.�osigni�cantassociationsbetweenchangesin
T2-LV and CV were found in either of these groups over the
followup.
3.4.BimonthlyEﬀectofCorticalVolumeChangesonDisability
Progression. eresultsfromthemixedeﬀectmodelanalysis
between CV, WBV, and T2-LV bimonthly changes and
disabilityprogressionover2yearsaresummarizedinTable 4.
Based on the models, the bimonthly change in CV was
signi�cantly related to disability progression over the 2-
year study, aer adjusting for disease duration (𝑃𝑃 𝑛 𝑃𝑃𝑃𝑛).
However,asimilarmodelshowedthatWBVandT2-LVwere
notsigni�cantlyrelatedtodisabilityprogressionover2years.
Similar analyses were also performed in the two disease
durationgroups(earlyandlate)bothwithandwithoutage,as
a covariate. Signi�cant associations between changes in CV
and disability progression were found over the followup in
b o t ht h ee a r l ya n dl a t ed i s e a s ed u r a t i o ng r o u p s( 𝑃𝑃 𝑛 𝑃𝑃𝑃𝑛).Multiple Sclerosis International 5
T 3: Relationship between cortical volume at baseline and changes with lesion burden over the followup in patients with relapsing-
remitting multiple sclerosis.
CV Coeﬃcient Standard error 𝑇𝑇 𝑃𝑃 value
Baseline
Age at baseline −2373.48 438.79 −5.41 <0.0001
Disease duration −608.11 680.62 −0.89 0.37
T2-LV −1.39 0.28 −4.93 <0.0001
B a s e l i n et oy e a r1
Age at baseline −0.005 0.06 0.09 0.93
Disease duration −0.04 0.08 −0.48 0.63
% Change T2-LV 0.005 0.009 0.52 0.61
Y e a r1t oy e a r2
Age at baseline 0.04 0.05 0.70 0.48
Disease duration 0.08 0.08 1.02 0.31
% Change T2-LV 0.01 0.007 1.51 0.13
B a s e l i n et oy e a r2
Age at baseline 0.03 0.03 0.90 0.37
Disease duration 0.008 0.05 0.15 0.88
% Change T2-LV 0.002 0.004 0.74 0.46
LV: lesion volume; CV: cortical volume.
estatisticalanalysisbetweenT2-LVandCVwasperformedusingregression(baseline)andmixedeﬀectmodel(year1andyear2)analysesonallbi-monthly
serial MRI time points of the study.
e LVs are in milliliters.
T 4: Relationship between cortical volume and disability progression over 2 years in patients with relapsing-remitting multiple sclerosis.
Disability progression Coeﬃcient Standard Error 𝑇𝑇 𝑃𝑃 value
Disease duration 0.04 0.015 2.99 0.003
CV −0.001 0.0004 −2.57 0.01
Disease duration 0.05 0.015 3.11 0.002
WBV −0.0003 0.0002 −1.55 0.12
Disease duration 0.05 0.015 3.11 0.002
T2-LV 0.005 0.004 1.21 0.23
CV: cortical volume, WBV: whole brain volume, and LV: lesion volume.
estatisticalanalysisbetweenCVanddisabilityprogression,asmeasuredbyEDSS,wasperformedusingmixedeﬀectmodelanalysesonallbi-monthlyserial
MRI time points of the study over 2 years.
When adjusted for baseline CV, by using the changes in CV from baseline and every six months in our analysis, the association with disability progression
became nonsigni�cant in both early and late RRMS groups (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃).
e LVs are in milliliters.
When adjusted for baseline CV, by using the changes in
CV from baseline and every six months in our analysis, the
associationwithdisabilityprogressionbecamenonsigni�cant
in both early and late RRMS groups.
4. Discussion
isstudyshowedthatsigni�cantbimonthlycorticalatrophy
occurs in patients with early RRMS over 2 years. is �nding
is in line with a previous serial MRI study that investigated
theevolutionofGMatrophyovera9-monthperiod[19].e
developmentofcorticalatrophyoverthe2-yearfollowupwas
independent of T2-LV accumulation, and was signi�cantly
associated with disability progression. �o signi�cant MRI
changes between early and late disease duration groups
were detected over 2 years, except for increased T2-LV
accumulationbetweenbaselineandyear2intheearlydisease
duration group.
We performed this study as an exploratory study, and
giventhatwedidnotknowhowmanycomparisonswewould
make a priori, we did not adjust the signi�cance tests for
multiplecomparisons.�otentialassociationsidenti�edinthe
current study may drive future research with preplanned
analyses to validate the results of this exploratory research.
e ASA was an investigator-initiated, prospective, lon-
gitudinal, double-blind, placebo-controlled study that was
originally designed to be 2 years in duration, but due to
slow recruitment, it was extended to a 5-year double-blind,
placebo-controlled design [18, 25, 26] and to a 10-year open-
label phase follow-up [27]. At the 5-year followup, 162 of 181
patients participating in the study had complete clinical and
MRI followup. MRI assessments a�er the �rst 2 years of the6 Multiple Sclerosis International
studywereperformedannuallyandtheclinicalexaminations
quarterly up to year 10. e 10-year followup of all subjects
originally enrolled in the study is scheduled to be completed
in late 2013. e �rst 136 of 181 patients enrolled in the ASA
studyparticipatedinabimonthlyserialMRIstudythataimed
to investigate early changes of MRI outcomes in relation to
short- and long-term clinical outcomes over 2, 5, and 10
years.
Oneofthemaingoalsinthepresentstudywastoexamine
the changes in cortical atrophy in patients with disease
duration of ≤24 or >2 4m o n t h sv i at h eu s eo fb i m o n t h l y
MRI scanning. An advantage of using the random eﬀects
mixed model is that it allows each subject observed in the
study to have its own mean, rather than assuming that all
subjects in the study have the same mean structure over the
course of the study. Our initial hypothesis was that, based
on a recently published study, [15] the evolution of cortical
atrophywillbeongoingataslowerrateintheearly,compared
to the late, disease duration group. In that study, it was
found that 212 patients with clinically isolated syndrome at
�rst clinical onset had similar CV to the 177 early RRMS
participating in the ASA study that were of the similar age,
although they had less than 5 years of disease duration. In
thepresentstudy,thelatediseasedurationgroupshowedthat
signi�cantly decreased CV compared to the early group at
baseline. However, there was almost 5 years of age diﬀerence
between the early and late disease duration groups. Over the
2-year followup, both groups developed signi�cant cortical
atrophy (Figure 1)a n dt h ee a r l yg r o u ps h o w e das l i g h t l y
increased, though not signi�cant, rate (−2.48%) compared to
the late group (−2.12%). ese �ndings suggest that cortical
atrophydevelopsatasimilarrateinRRMSpatientswithearly
andlatediseaseduration.ecurrentandpreviousstudy[15]
indicate that age may play an important role in development
of cortical atrophy in MS patients and should be taken into
account in future studies.
Placebo-controlled clinical studies have shown that IM
IFN𝗽𝗽-1a reduces T2 LV [31], slows disability progression,
[32], and prevents development of brain atrophy [33–36].
However, despite these known eﬀects of treatment with IM
IFN𝗽𝗽-1a, both the early and late disease duration groups of
MS patients exhibited loss of brain tissue and, in particular,
developed cortical atrophy over the 2 years in the present
study. However, the present study showed most of the WB
and CV volume changes occurred in the �rst year of the
study (Table 2). is phenomenon could be related to a
�pseudoatrophy eﬀect,� which was described in the �rst year
ofthestudyinmostofrecentMSclinicaltrialsusingdisease-
modifying treatment [37]. is could have contributed to
accelerated volume changes observed in the WB and CV
volumes in the �rst year in the present study. In the second
year of the study, a treatment eﬀect may have taken place, as
previouslydescribedwithuseofIMIFN𝗽𝗽-1a[35].eextent
of cortical atrophy development in untreated MS patients
is likely to be greater than that observed in the treated
patientsinthisstudy.Apreviouscase-controlstudysuggested
that IM IFN𝗽𝗽-1a may slow down GM atrophy progression
[36].
GMatrophydevelopmentisabetterindicatorofdisability
progressionthanaccumulationoflesionburdenorWMatro-
phy [16–18]. It has been shown that cognitive impairment
in patients with RRMS is thought to be associated with MS-
related GM pathology, particularly in the cortex [38], with
variability in disability progression between patients with
RRMS possibly arising from diﬀerences in GM injury. In the
presentstudy, we found, in a mixed eﬀect model analysis that
includedallbimonthlyserialMRItimepointsover24months
and corrected for disease duration, that cortical atrophy
was signi�cantly associated with development of disability
progression, as determined by 12-week sustained worsening
at month 27. However, when adjusted for baseline CV, by
using the changes in CV from baseline and every six months
in our analysis, this association became nonsigni�cant in
bothstudygroups.is�ndingsuggeststhatcorticalatrophy
at baseline plays an important role in subsequent disability
development over 2 years. As such, the study may have
important implication for identifying patients at higher risk
fordisabilityprogression.Ontheotherhand,developmentof
wholebrainatrophyoraccumulationofT2-LVoverthesame
period did not show a signi�cant association. e �ndings
were similar in both the early and late disease duration
groups.isisindeedanimportant�nding,asitsuggeststhat
disabilityprogressionover2yearsintheearlyphaseofRRMS
may be predominantly related to cortical atrophy.
In the mixed eﬀect model analysis, corrected for age
and disease duration, no association was found between
development of cortical atrophy and accumulation of lesion
burden, when all bimonthly serial MRI time points over 24
months were included. Separate models showed no diﬀerent
outcomes, when only age was used as a covariate, in models
that were run on the early or late disease duration groups.
is �nding indicates that cortical atrophy develops inde-
pendently of T2-LV accumulation over 2 years. However, in
regression analysis, there was a robust relationship between
the amount of cortical atrophy and lesion burden at baseline.
is indicates that development of cortical atrophy may
be associated with T2-LV accumulation, but that a longer
period of time may be needed to assess this relationship
longitudinally. However, the 5-year results of the preliminary
extension of the ASA study [18, 26] argue against an associa-
tion of T2-LV accumulation with GM atrophy even over a 5-
yearfollowup.AlthoughthecurrentstudydidnotuseDIRfor
detectionofcorticallesions,the2D-FLAIRsequencethatwas
usedhad1.5mmthickness.Ithasbeenshownpreviouslythat
this sequence has higher sensitivity for detection of cortical
and WM lesions than standard MRI protocol [23].
Although there are several strengths to this study, includ-
ing bimonthly serial MRI acquisition and prospective and
longitudinal design of the study, there are important limits
to be considered. e choice of the classi�cation of early
RRMS patients in the early and late disease duration groups
was arbitrary, as our goal was to investigate whether patients
withdiseasedurationoflessthan24monthshadevolutionof
cortical atrophy similar to those with more than 24 months.
is created two groups of uneven sample size (37 versus 99
subjects) and relapse activity in the previous year that could
have in�uenced to some extent our �ndings. It could be thatMultiple Sclerosis International 7
other classi�cation criteria, for example, by median disease
duration (3.9 years), could have yielded diﬀerent results.
However, this is unlikely, as the MRI changes in individual
and total groups were very similar. Use of DIR could also
have helped to better estimate the amount of cortical lesion
pathology[5–9];however,whenthisstudywasdesigned,DIR
was not yet available. We did not investigate cognitive out-
comes in this study. Neuropsychological assessment would
be potentially more relevant for association with cortical
atrophy, especially in archicortical areas [39, 40].
Inconclusion,signi�cantcorticalatrophy,independentof
T2-LV accumulation, occurs in early RRMS over 2 years, and
it is associated with disability progression.
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